ATG5: A Potential Drug Target Or Biomarker (G9474)

Target Name: ATG5

NCBI ID: G9474

ATG5

ATG5: A Potential Drug Target Or Biomarker

ATG5 (ATG5 variant 2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the ATG5 family, which is characterized by the presence of a unique nucleotide sequence at its C-terminus. In this article, we will discuss ATG5 as a potential drug target or biomarker, with a focus on its biology, structure, and potential therapeutic applications.

Structure and Expression

ATG5 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and kidney. It is characterized by the presence of a unique nucleotide sequence at its C-terminus, which consists of a GCAATGCA repeat. This sequence is also found in several other proteins, including ATG5 variant 1 and 2, which are both involved in the detoxification of xenobiotics.

ATG5 is expressed in various tissues of the body and is involved in a variety of physiological processes. In the brain, it is involved in the regulation of synaptic plasticity and in the development of neurodegenerative diseases. In the heart, it is involved in the regulation of contractility and in the development of heart failure. In the liver, it is involved in the detoxification of xenobiotics and in the regulation of metabolism. In the kidney, it is involved in the regulation of water and electrolyte balance.

Potential Therapeutic Applications

ATG5 is a protein that has potential as a drug target or biomarker due to its involvement in a variety of physiological processes. One potential therapeutic application of ATG5 is as a drug target for diseases that are characterized by the over-expression of ATG5. For example, ATG5 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, inhibiting the expression of ATG5 could be a potential therapeutic approach for these diseases.

In addition to its potential as a drug target, ATG5 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been used as a biomarker for diseases characterized by the over-expression of ATG5, such as neurodegenerative diseases, cancer, and cardiovascular disease. In addition, ATG5 has been shown to be involved in the regulation of various physiological processes, including the detoxification of xenobiotics and the regulation of metabolism. Therefore, measuring the expression of ATG5 could be a potential biomarker for a variety of diseases.

Conclusion

ATG5 is a protein that is expressed in various tissues of the body and has potential as a drug target or biomarker. Its unique nucleotide sequence and its involvement in various physiological processes make it an attractive target for therapeutic applications. Further research is needed to fully understand the biology and potential therapeutic applications of ATG5.

Protein Name: Autophagy Related 5

Functions: Involved in autophagic vesicle formation. Conjugation with ATG12, through a ubiquitin-like conjugating system involving ATG7 as an E1-like activating enzyme and ATG10 as an E2-like conjugating enzyme, is essential for its function. The ATG12-ATG5 conjugate acts as an E3-like enzyme which is required for lipidation of ATG8 family proteins and their association to the vesicle membranes. Involved in mitochondrial quality control after oxidative damage, and in subsequent cellular longevity. Plays a critical role in multiple aspects of lymphocyte development and is essential for both B and T lymphocyte survival and proliferation. Required for optimal processing and presentation of antigens for MHC II. Involved in the maintenance of axon morphology and membrane structures, as well as in normal adipocyte differentiation. Promotes primary ciliogenesis through removal of OFD1 from centriolar satellites and degradation of IFT20 via the autophagic pathway

The "ATG5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets